[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556326":3},{"organization":4,"outcomesModule":7,"designInfo":67,"detailedDescription":11,"studyPopulation":69,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":70,"locations":80,"responsibleParty":138,"collaborators":11,"id":140,"slug":11,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":11,"eligibilityCriteria":145,"healthyVolunteers":141,"sex":146,"minAge":147,"maxAge":11,"enrollmentInfo":148,"targetDuration":11,"studyType":151,"phases":11,"briefSummary":152,"conditions":153,"keywords":11,"overallStatus":83,"whyStopped":11,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},{"fullName":5,"class":6},"Kazakhstan Scientific Society for Study of intestine diseases","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The proportion of patients with a reduced level of disease activity by 30% or more according to the Crohn's Disease Activity Index",null,"at week 24 of therapy",[14,17,20,22,25,28,31,34,37,39,41,43,45,47,49,51,53,55,57,59,61,63,65],{"measure":15,"description":11,"timeFrame":16},"Proportion of patients with a 30% or more reduction in disease activity according to the Crohn's Disease Activity Index","at 12 and 52 weeks of therapy",{"measure":18,"description":11,"timeFrame":19},"Proportion of patients in endoscopic remission based on Simple Endoscopic Score for Crohn's Disease","at 24 and 52 weeks",{"measure":21,"description":11,"timeFrame":19},"Dynamics of fecal calprotectin levels",{"measure":23,"description":11,"timeFrame":24},"Proportion of patients with normalization of Magnetic resonance enterography based on the Magnetic Resonance Index of Activity","at 12 and 52 weeks",{"measure":26,"description":11,"timeFrame":27},"Dynamics of quality of life assessment based on the Short Inflammatory Bowel Disease Questionnaire","at 12, 24 and 52 weeks",{"measure":29,"description":11,"timeFrame":30},"Dynamics of antibody synthesis to the drug Ustekinumab","at 0\u002F1, 24 and 52 weeks",{"measure":32,"description":11,"timeFrame":33},"List of medications indicated in the general scheme with Odeston","through study completion, an average of 1 year",{"measure":35,"description":11,"timeFrame":36},"Dynamics of assessing patient adherence to treatment using the Morisky-Green scale","at 0\u002F1, 12, 24 and 52 weeks",{"measure":38,"description":11,"timeFrame":33},"Collection of information on adverse reactions and\u002For registration of pregnancy cases",{"measure":40,"description":11,"timeFrame":19},"Dynamics of red blood cell parameters",{"measure":42,"description":11,"timeFrame":19},"Dynamics of hemoglobin parameters",{"measure":44,"description":11,"timeFrame":19},"Dynamics of platelet parameters",{"measure":46,"description":11,"timeFrame":19},"Dynamics of leukocyte parameters with leukocyte formula",{"measure":48,"description":11,"timeFrame":19},"Dynamics of erythrocyte sedimentation rate parameters",{"measure":50,"description":11,"timeFrame":19},"Dynamics of potassium parameters",{"measure":52,"description":11,"timeFrame":19},"Dynamics of sodium parameters",{"measure":54,"description":11,"timeFrame":19},"Dynamics of C-reactive protein parameters",{"measure":56,"description":11,"timeFrame":19},"Dynamics of albumin parameters",{"measure":58,"description":11,"timeFrame":19},"Dynamics of total protein parameters",{"measure":60,"description":11,"timeFrame":19},"Dynamics of serum iron parameters",{"measure":62,"description":11,"timeFrame":19},"Dynamics of serum iron-binding capacity parameters",{"measure":64,"description":11,"timeFrame":19},"Dynamics of vitamin B9 parameters",{"measure":66,"description":11,"timeFrame":19},"Dynamics of Nutritional Risk Index indicators",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":6,"timePerspective":68,"maskingInfo":11},"PROSPECTIVE","The study will include male and female patients aged 18 years and older, with a confirmed diagnosis of Crohn's disease, on therapy with the drug Ustekinumab",[71,76],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},"Kanat Khazhidinov","CONTACT","+7 707 413 8263","kanat.khazhidinov@smo-mera.kz",{"name":77,"role":73,"phone":78,"phoneExt":11,"email":79},"Yekaterina Sakhabutdinova","+7 707 375 8530","yekaterina.sakhabutdinova@smo-mera.kz",[81,98,112,125],{"facility":82,"status":83,"city":84,"state":11,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"NJSC \"West Kazakhstan Marat Ospanov Medical University\"","RECRUITING","Aktobe","Kazakhstan","KZ",{"type":88,"coordinates":89},"Point",[90,91],57.20718,50.27969,{"lat":91,"lon":90},[94],{"name":95,"role":73,"phone":96,"phoneExt":11,"email":97},"Aset Kaliev","+7 (7132) 563425","info@.zkmu.kz",{"facility":99,"status":83,"city":100,"state":11,"zip":101,"country":85,"countryCode":86,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Non-Profit Joint Stock Company \"Kazakh National Medical University named after S.D. Asfendiyarov\"","Almaty","055990",{"type":88,"coordinates":103},[104,105],76.9115,43.25249,{"lat":105,"lon":104},[108],{"name":109,"role":73,"phone":110,"phoneExt":11,"email":111},"Marat Shoranov","+7(727)338-70-90","info@kaznmu.kz",{"facility":113,"status":83,"city":114,"state":11,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"State-owned public enterprise with the right of economic management \"Multidisciplinary City Hospital No. 1\" of the Akimat of Astana","Astana",{"type":88,"coordinates":116},[117,118],71.44598,51.1801,{"lat":118,"lon":117},[121],{"name":122,"role":73,"phone":123,"phoneExt":11,"email":124},"Marat Abduov","+7(7172) 27 20 28","gb1-astana@mail.ru",{"facility":126,"status":83,"city":127,"state":11,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"State-owned public enterprise with the right of economic management \"Regional Clinical Hospital\" of the Health Department of the Turkestan Region","Shymkent",{"type":88,"coordinates":129},[130,131],69.60042,42.30988,{"lat":131,"lon":130},[134],{"name":135,"role":73,"phone":136,"phoneExt":11,"email":137},"Zhanbolat Dildabekov","+7 (7252) 53 78 99","gkkp-okb@mail.ru",{"type":139,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100556326",false,"NCT06523647","Clinical Efficacy of Ustekinumab in Crohn's Disease","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components","Inclusion Criteria:\n\n* Patients aged 18 years and older;\n* Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024\n* Patients who provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindications to the use of the drug Ustekinumab per the current instructions:\n\n  * Clinically significant active infection (active tuberculosis, active viral hepatitis);\n  * Pregnancy and lactation;\n  * A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen;\n  * Ulcerative colitis;\n  * Malignant gastrointestinal diseases in history or at the time of inclusion in the study;\n  * Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus;\n  * Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient);\n* Participation in an interventional clinical trial.","ALL","18 Years",{"count":149,"type":150},150,"ESTIMATED","OBSERVATIONAL","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components.",[154],"Crohn's Disease","2024-07-23",{"date":157,"type":158},"2024-07-26","ACTUAL",{"date":160,"type":158},"2023-06-27",{"date":162,"type":150},"2025-12",{"name":5,"class":6},4]